Editor – What is the impact of changing anticoagulation from warfarin to direct-acting oral anticoagulants (DOAC) on the carbon footprint (CF) of the elective direct current cardioversion (EDCCV) care pathway (supplementary material S1; Fig S1)?
Methods
After Integrated Research Application System (230497), institutional approval (RHM-CR10347) and patient consent, we recruited all patients presenting for EDCCV under general anesthesia at University Hospital Southampton NHS Foundation Trust (UHS) between 2012–2017. Prospectively, data from 22 patients were analysed: mode of transport to their general practitioner and UHS, anaesthesia drugs, disposables, oxygen, waste generation and time spent in hospital for EDCCV were obtained and applied retrospectively. From the information systems, correspondence, attendance, duration of stay, clinical activity and pathology data was obtained, extracted, anonymised and encrypted. We calculated all relevant distances, (supplementary material S1; Tables S1 and S2) and incorporated these into Sustainable Care Pathway Guidance (SCPG).1 Pooled data for DOAC treated patients were compared with warfarin treated patients using the Mann–Whitney U test.
Study answer and limitations
Supplementary material S1, Fig S2 illustrates patient flow. In the prospective limb, 21 travelled to hospital and 14 to their GP surgery by fossil fuelled cars. Median age was 68 years (interquartile range (IQR) 61–73; range 22–89), 71.6% were men and 204 were receiving DOACs at the time of the EDCCV.
DOAC treated patients spent less time on the care pathway, made fewer visits to GP and hospital, travelled less and had fewer coagulation studies. The median equivalent carbon dioxide (CO2e) was 58.16 kg vs 85.49 kg for the warfarin group (p<0.0001; Table 1; Fig 1).
Total kgCO2e of the care pathways for warfarin vs DOAC treated patients. DOACs = direct acting oral anticoagulants (and includes the pooled results from the patients receiving rivaroxaban, apixaban and dabigatran).
Warfarin and DOAC treated groups
Between 2012–2017, DOAC treatment required less stringent monitoring of anticoagulation with less visits, travelling, sample transportation and processing. The CO2e of anaesthesia-related single use items was taken as 420 g/£ spent irrespective of anticoagulation.2 The CO2e of DOAC procurement was not available from the manufacturers, but we estimate a month's apixaban therapy to be 100 g (1 km in a small car).3–5
Building energy use was apportioned for the duration of stay and was 233 kWh/bed/day and contributed 17.11 kg for both groups.6
What this study adds
SCPG avoids time-consuming and costly life cycle assessments, yet provides the framework to map clinical care. The change from warfarin to DOACs reduced the CF of the EDCCV care pathway for patients attending our hospital.
Supplementary material
Additional supplementary material may be found in the online version of this article at www.rcpjournals.org/fhj:
S1 – Supplemental tables and figures.
Acknowledgement
The authors gratefully acknowledge the help and support provided by Simon Aumônier of ERM, Oxford, UK.
- © Royal College of Physicians 2021. All rights reserved.
Article Tools
Jump to section
Related Articles
Cited By...
- No citing articles found.